TokenPost·

Biogen’s Diranersen Data Show Slower Alzheimer’s Decline Over Two Years

Your call?

The Phase 2 open-label extension showed a 38% improvement in clinical benefit with a 60 mg regimen given twice yearly.

Share

More news